Burping on Foundayo™

The eructation row and the documents around it

Table 1 in section 6.1 pools two placebo-controlled weight trials of up to 72 weeks, ATTAIN-1 in adults without diabetes and ATTAIN-2 in adults with type 2 diabetes, and lists reactions seen in at least 5% of treated people and more often than on placebo ^[1]. Eructation is one of its 13 rows. The Medication Guide puts belching on its list of the most common side effects ^[2].

No other regulator has published figures. The European Medicines Agency’s committee recommended approval on 15 October 2026, but there is no EMA product information yet ^[3], and Health Canada’s database has no Foundayo™ or orforglipron entry ^[4].

How large the jump really is

Placebo burping was the lowest background rate in the whole table, so even a modest number on the tablet is a big multiple of it. Using the label’s whole-number percentages, burping on Foundayo™ was six times placebo on 5.5 mg and eight times on 9 mg and 17.2 mg. For comparison, nausea reached about three and a half times placebo and vomiting six times, both on the top dose ^[1].

Rounded percentages can exaggerate or shrink a ratio, so it helps to go back to counts. The two trial registries together list 14 of 1,576 people on placebo with burping, about 0.9%, and 65 of 1,051 (6.2%), 81 of 1,055 (7.7%) and 83 of 1,049 (7.9%) on the three doses, which matches the label’s rounded figures ^[5][6]. In absolute terms, burping added about five to seven people per hundred; nausea added far more. So burping affected fewer people than the headline stomach reactions but was the most specific to the tablet.

The rate rose between 5.5 mg and 9 mg and then stayed flat ^[1]. The label’s dose schedule moves up in steps at least 30 days apart to limit stomach and bowel reactions, so the weeks after the step to 9 mg are a sensible place to look in your own notes ^[1].

Trial by trial

The trials used an investigational formulation. In ATTAIN, the 6, 12 and 36 mg trial doses correspond to Foundayo™ 5.5, 9 and 17.2 mg ^[1]; the ACHIEVE diabetes trials also tested a 3 mg dose that has no stated tablet equivalent.

What the comparison shows

• Every trial points the same way: burping was uncommon on placebo and several times more frequent on orforglipron ^[5][6][8].
• The highest figure, 11.5% in ATTAIN-2, came on the middle dose rather than the top one ^[6]. The registries do not explain this, and groups of about 330 people leave room for chance.
• Oral semaglutide also caused burping in ACHIEVE-3, but about half as often ^[7]. The trial publication reports more stomach and bowel events overall on orforglipron, 59% and 58%, than on semaglutide, 37% and 45% ^[9].
• ACHIEVE-3 was open label, so participants knew which tablet they took, which can influence reporting ^[9]. It also studied type 2 diabetes, which the US label does not cover; the EU opinion does include it ^[1][3].

Why a slower stomach may bring up more air

• From the label: Foundayo™ delays stomach emptying, most after the first dose and less as treatment goes on ^[1]. The label does not link eructation to this by name.
• Plausible but not measured: MedlinePlus explains that a belch happens when air stretches the upper stomach and the muscle at the lower end of the oesophagus relaxes to let it out ^[10], and Cleveland Clinic lists gastroparesis, a slow-moving stomach, among conditions that cause belching ^[11]. No orforglipron study has tested whether slower emptying is what drives the extra burping.
• General knowledge: belching is a normal way of releasing swallowed air, and MedlinePlus notes it can relieve nausea, indigestion or heartburn ^[10].

Other reasons for frequent burping

Burping often comes with its table neighbours, indigestion (12% to 16%) and reflux disease (6% to 7%), both linked to belching in general sources and covered on our Foundayo™ heartburn page ^[1][11].

Cleveland Clinic names swallowed air as the most common cause of excessive belching: eating or drinking quickly, talking while eating, chewing gum, sucking hard sweets, fizzy drinks, smoking, loose dentures, postnasal drip, mouth breathing, snoring and CPAP use ^[11]. Snoring and CPAP are worth a thought here, because 11% of people in the Foundayo™ trials had obstructive sleep apnoea ^[1]. Beans, lentils, cabbage, onions, broccoli and cauliflower can add to it, as can gastritis, peptic ulcers, lactose intolerance, H. pylori infection, small intestinal bacterial overgrowth and anxious air swallowing ^[11].

What general sources say helps

MedlinePlus suggests lying on your side or in a knee-to-chest position until the gas passes, and avoiding chewing gum, eating quickly and gas-producing foods and drinks ^[10]. Cleveland Clinic adds sitting down to eat and taking your time, cutting back on fizzy drinks and alcohol, and regular exercise that strengthens the core ^[11]. If belching is excessive and does not go away, it says a provider may look for an underlying condition and may suggest avoiding certain foods, a low-FODMAP plan or a dietitian ^[11].

Neither source names a medicine for burping. If you are thinking of taking something from the pharmacy, ask the pharmacist first: the Foundayo™ label says the tablet slows stomach emptying and can change how other oral medicines are absorbed ^[1].

What the label leaves out

• Smell or taste: neither the label nor the Medication Guide describes the character of the burps ^[1][2]. The label does report a separate taste change, dysgeusia, in 0.9% on Foundayo™ against 0.3% on placebo ^[1].
• Timing: its sentence about reactions easing over time names nausea, vomiting and diarrhoea, not burping ^[1].
• Stopping: there is no figure for burping alone. All stomach and bowel reactions together led 3% to 6% of people on Foundayo™ to stop, against 0.7% on placebo ^[1].

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help